Innovative approach against cancer: Thymoquinone-loaded PHEMA-based magnetic nanoparticles and their effects on MCF-7 breast cancer
| dc.contributor.author | Yıldırım, Metin | |
| dc.contributor.author | Acet, Ömür | |
| dc.contributor.author | Önal Acet, Burcu | |
| dc.contributor.author | Karakoç, Veyis | |
| dc.contributor.author | Odabaşı, Mehmet | |
| dc.date.accessioned | 2024-08-26T10:26:55Z | |
| dc.date.available | 2024-08-26T10:26:55Z | |
| dc.date.issued | 2024 | |
| dc.department | Sabire Yazıcı Fen Edebiyat Fakültesi | |
| dc.description.abstract | Breast cancer is most common cancer among women in the World. Thymoquinone (TQ) exhibits a wide range of biological activities such as anticancer, antidiabetic, antimicrobial, analgesic, antioxidant, and anti-inflammatory effects. However, its effectiveness in cancer treatment is hindered by its poor bioavailability, attributed to its limited solubility in water. Hence, novel strategies are required to enhance the bioavailability of TQ, which possesses remarkable anticancer characteristics. The aim of this study is to prepare pHEMA-based magnetic nanoparticles carrying TQ (TQ-MNPs) to improve bioavailability, and therapeutic efficacy against breast cancer. For this purpose, TQ-MNPs were synthesized and characterized with Fourier transform infrared spectrophotometer (FTIR), scanning electron microscopy (SEM), dynamic light scattering (DLS), magnetic field using a vibrating sample magnetometer (VSM). The loading capabilities of synthesized magentic nanostructures were evaluated, and release investigations were conducted under experimental conditions that mimic the cellular environment. The findings of the studies indicated that the TQ carrying capacity of MNPs was deemed satisfactory, and the release efficiency was adequate. MNPs and TQ-MNPs showed biocompatibility against HDFa cells. TQ-MNPs showed stronger anti-proliferative activity against MCF-7 breast cancer cells compared to free TQ (p < 0.05). TQ-MNPs induced apoptosis in MCF-7 breast cancer cells. | |
| dc.identifier.doi | 10.1016/j.bbrc.2024.150464 | |
| dc.identifier.issn | 0006-291X | |
| dc.identifier.scopusquality | Q2 | |
| dc.identifier.uri | https:/dx.doi.org/10.1016/j.bbrc.2024.150464 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12451/12375 | |
| dc.identifier.volume | 734 | en_US |
| dc.identifier.wosquality | N/A | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.language.iso | en | |
| dc.publisher | Elsevier B.V. | |
| dc.relation.ispartof | Biochemical and Biophysical Research Communications | |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/embargoedAccess | |
| dc.subject | Cancer | |
| dc.subject | Magnetic Nanoparticles | |
| dc.subject | MCF-7 | |
| dc.subject | Thymoquinone | |
| dc.title | Innovative approach against cancer: Thymoquinone-loaded PHEMA-based magnetic nanoparticles and their effects on MCF-7 breast cancer | |
| dc.type | Article |
